Science News
from research organizations

Creatine does not slow rate of Parkinson disease progression

Date:
February 10, 2015
Source:
JAMA - Journal of the American Medical Association
Summary:
Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a new study.
Share:
FULL STORY

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

Parkinson disease is a progressive neurodegenerative disorder that affects approximately 6 million people worldwide and more than one-half million individuals in the United States. Incidence is expected to increase over the next decade, but neither a cure nor a treatment is available that has been proven to slow progression. Evidence indicates that creatine, an amino acid, plays an important role in cellular energy production, which may be impaired in Parkinson disease. Oral creatine supplementation in mice has suggested a neuroprotective effect, according to information in the article.

Karl Kieburtz, M.D., M.P.H., of the University of Rochester, Rochester, N.Y., and colleagues, randomly assigned 1,741 men and women with early (within 5 years of diagnosis) and treated (receiving dopaminergic therapy) Parkinson disease to receive placebo or creatine monohydrate (10 g/d) for a minimum of 5 years (maximum follow-up, 8 years). Participants were recruited from 45 investigative sites in the United States and Canada, enrolled from March 2007 to May 2010, and followed up until September 2013.

The trial was terminated early for futility based on results of a planned interim analysis of participants enrolled at least 5 years prior to the date of the analysis (n = 955).The median follow-up time was 4 years. Using several measures of Parkinson disease progression, the researchers found that treatment with creatine, compared with placebo, did not improve clinical outcomes.

There were no detectable differences in adverse and serious adverse events by body system.


Story Source:

Materials provided by JAMA - Journal of the American Medical Association. Note: Content may be edited for style and length.


Journal Reference:

  1. Karl Kieburtz, Barbara C. Tilley, Jordan J. Elm, Debra Babcock, Robert Hauser, G. Webster Ross, Alicia H. Augustine, Erika U. Augustine, Michael J. Aminoff, Ivan G. Bodis-Wollner, James Boyd, Franca Cambi, Kelvin Chou, Chadwick W. Christine, Michelle Cines, Nabila Dahodwala, Lorelei Derwent, Richard B. Dewey, Katherine Hawthorne, David J. Houghton, Cornelia Kamp, Maureen Leehey, Mark F. Lew, Grace S. Lin Liang, Sheng T. Luo, Zoltan Mari, John C. Morgan, Sotirios Parashos, Adriana Pérez, Helen Petrovitch, Suja Rajan, Sue Reichwein, Jessie Tatsuno Roth, Jay S. Schneider, Kathleen M. Shannon, David K. Simon, Tanya Simuni, Carlos Singer, Lewis Sudarsky, Caroline M. Tanner, Chizoba C. Umeh, Karen Williams, Anne-Marie Wills. Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease. JAMA, 2015; 313 (6): 584 DOI: 10.1001/jama.2015.120

Cite This Page:

JAMA - Journal of the American Medical Association. "Creatine does not slow rate of Parkinson disease progression." ScienceDaily. ScienceDaily, 10 February 2015. <www.sciencedaily.com/releases/2015/02/150210130145.htm>.
JAMA - Journal of the American Medical Association. (2015, February 10). Creatine does not slow rate of Parkinson disease progression. ScienceDaily. Retrieved May 30, 2017 from www.sciencedaily.com/releases/2015/02/150210130145.htm
JAMA - Journal of the American Medical Association. "Creatine does not slow rate of Parkinson disease progression." ScienceDaily. www.sciencedaily.com/releases/2015/02/150210130145.htm (accessed May 30, 2017).

RELATED STORIES